• argenx agreed to buy Forte Biosciences in an all-cash deal valued at about USD 2.2 billion.
• Forte shareholders will receive USD 77 per share, an 86% premium to the VWAP since July 9, 2026.
• The acquisition adds Forte’s lead asset FB102, a first-in-class anti-CD122 antibody with Phase 1b data in vitiligo and celiac disease.
• The deal is expected to close in Q3 2026; funding will come from argenx cash on hand.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. arGEN-X SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607270100PRIMZONEFULLFEED1001244498) on July 27, 2026, and is solely responsible for the information contained therein.